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Summary
Protein farnesyltransferase (FTase) is an enzyme responsible for posttranslational modification of proteins carrying a
carboxy-terminal CaaX motif. Farnesylation allows substrates to interact with membranes and protein targets. Using
gene-targeted mice, we report that FTase is essential for embryonic development, but dispensable for adult homeostasis.
Six-month-old FTase-deficient mice display delayed wound healing and maturation defects in erythroid cells. Embryonic
fibroblasts lacking FTase have a flat morphology and reduced motility and proliferation rates. Ablation of FTase in two ras
oncogene-dependent tumor models has no significant consequences for tumor initiation. However, elimination of FTase
during tumor progression had a limited but significant inhibitory effect. These results should help to better understand
the role of protein farnesylation in normal tissues and in tumor development.S I G N I F I C A N C E
A significant number of proteins, including the Ras family, are isoprenylated, a posttranslational modification that is required for
proper localization within membrane structures. Among isoprenylating enzymes, protein farnesyltransferase (FTase) has received
most attention, since it can be targeted for pharmacological intervention to block transformation by Ras oncoproteins. Indeed,
FTase inhibitors have been developed for over a decade and will be approved soon for clinical use. Here, we provide genetic
evidence that FTase activity is essential for embryonic proliferation, but not for adult homeostasis. Surprisingly, FTase is not required
for tumor induction by ras oncogenes. Yet, ablation of FTase during tumor progression results in significant tumor reduction. These
findings should stimulate further work to better understand the role of protein farnesylation in cancer.Introduction
Posttranslational modification of eukaryotic proteins by iso-
prenyl residues was firmly established in the late 80s (reviewed
in Glomset et al., 1990; Zhang and Casey, 1996). Eukaryotic
organisms, from yeast to man, contain three protein isopren-
yltransferases, designated protein farnesyltransferase (FTase),
protein geranylgeranyltransferase I (GGTase I), and protein ger-
anylgeranyltransferase II (GGTase II). These enzymes are clas-
sified based on the isoprenyl group, farnesyl (C15) or geranyl-
geranyl (C20), that they use as a substrate as well as on the
motif that they recognize. FTase and GGTase I (collectively
known as CaaX prenyltransferases) recognize a CaaX motif
where C is a cysteine residue, a is a small aliphatic amino acid,
and X is the carboxy-terminal residue that contributes to sub-
strate specificity. These enzymes are heterodimeric complexes
comprised of a common regulatory (α subunit) and a unique
catalytic (β subunit) subunit. In all cases, the isoprenyl group is
attached to the protein by a thioether bond to the cysteine
residue (Zhang and Casey, 1996).
Many substrates of CaaX prenyltransferases are involved inCANCER CELL : APRIL 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INCcellular pathways whose dysfunction often leads to disease.
Among the best-known farnesylated proteins are Ras proteins,
nuclear lamins, kinetochore proteins such as CENP-E and
CENP-F, cGMP phosphodiesterase α, the γ subunits of
two heterotrimeric G proteins, DnaJ heat shock protein homo-
logs, rhodopsin kinase, and peroxisomal membrane proteins.
GGTase I geranylgeranylates most of the members of the Rho
subfamily of small GTPases, certain γ subunits of heterotri-
meric G proteins, and cGMP phosphodiesterase α (Reid et al.,
2004). Whereas FTase recognizes proteins with CaaX motifs in
which X is a serine, methionine, alanine, or glutamine residue,
GGTase I favors CaaX motifs in which the carboxy-terminal
residue is a leucine (Seabra et al., 2002). However, enzyme
specificity is not absolutely stringent, and there are abundant
examples of protein crossprenylation (Zhang and Casey, 1996).
For instance, K-Ras4B oncoproteins presumably escape func-
tional inhibition by FTase inhibitors (FTIs) due to geranylgeran-
ylation of its carboxy-terminal methionine by GGTase I (Lerner
et al., 1997; Rowell et al., 1997; Whyte et al., 1997). Other pro-
teins, such as RhoB, are substrates for both FTase and GGTase
I (Armstrong et al., 1995). More importantly, farnesylated RhoB. DOI 10.1016/j.ccr.2005.03.004 313
A R T I C L Eappears to have a different mechanism of action than its gera-
nylgeranylated isoform (Du et al., 1999; Lebowitz et al., 1995),
thus indicating that protein isoprenylation may confer distinct
biological properties, at least to certain substrates (reviewed in
Prendergast, 2001).
Among protein isoprenyltransferases, FTase has received
special attention, since it is responsible for isoprenylating the
Ras proteins implicated in a significant percentage of human
cancers (reviewed in Downward, 2003; Sebti and Der, 2003).
Early structure/function studies had indicated that replacement
of the cysteine residue present in the CaaX motif of Ras onco-
proteins by serine completely abolished their transforming ac-
tivity in vitro (Willumsen et al., 1984a; Willumsen et al., 1984b).
Later studies indicating that this cysteine residue was the site
of modification by a farnesyl isoprenoid (Casey et al., 1989;
Hancock et al., 1989) prompted the hypothesis that blocking
farnesylation may have therapeutic benefit for cancer patients
carrying ras oncogenes (reviewed in Gibbs et al., 1994). FTIs
inhibited or delayed tumor development in human tumor xeno-
grafts (Kohl et al., 1994) and in H-ras transgenic models (Kohl
et al., 1995) with few toxic effects. Several FTIs were rapidly
taken to the clinic, and some of them are in phase III clinical
trials (Downward, 2003). However, these compounds have not
performed in the clinic to their initial expectations (Sebti and
Der, 2003). Moreover, the mechanism by which FTIs induce an-
titumor effects remains to be elucidated, since their antitumor
spectrum does not correlate with the presence of ras onco-
genes (Sebti and Der, 2003).
We undertook this work to establish the genetic bases for
the requirements of protein farnesylation in mammalian cells.
To this end, we have generated constitutive (germline) and con-
ditional (floxed) knockout strains of mice for the locus encoding
the catalytic β subunit of FTase. We report here that protein
farnesylation is essential for early embryonic proliferation but
dispensable for postnatal development and adult homeostasis.
Ablation of FTase in two ras oncogene-dependent tumor mod-
els has no significant consequences for tumor initiation. How-
ever, elimination of FTase during tumor progression had a lim-
ited but significant inhibitory effect. These observations have
important implications, not only for understanding the biologi-
cal significance of protein farnesylation in mammalian cells, but
also in providing a much needed model for assessing the value
of FTase as a target for cancer prevention and cancer therapy.
Results
Targeted disruption of the gene encoding the catalytic
subunit of FTase
We have targeted the catalytic β subunit of FTase in embryonic
stem (ES) cells by inserting three loxP sites flanking exon 3 and
a PGK-neo cassette (loxneo allele) (Figure 1A). Removal of
exon 3 causes a shift in the open reading frame leading to the
incorporation of 26 unrelated residues before encountering a
stop termination codon within exon 4 sequences. Crosses be-
tween FT+/loxneo and CMV-Cre transgenic mice (Schwenk et al.,
1995) removed all floxed sequences to generate FT+/− hetero-
zygous mice in 59 out of 62 newborn animals. In three mice,
the Cre recombinase only removed the floxed PGK-neo cas-
sette, thus generating the desired conditional allele (lox allele).
The presence of the null (−) and conditional (lox) alleles was314Figure 1. Gene targeting of the catalytic subunit of FTase
A: Genomic structure of the region encompassing exons 3 and 4 of the
locus encoding the catalytic subunit of the mouse FTase. Those sequences
included in the targeting vector are indicated by dotted lines. Exons 3 and
4 (filled boxes), PGK-neo cassette (open box), PGK-tk cassette (dotted
box), and loxP sequences (filled triangles) are indicated. A homologous
recombination event between the wild-type allele and the targeting vec-
tor yields the loxneo allele. The genomic structure of the conditional lox and
null alleles resulting from partial and complete Cre-mediated recombina-
tion, respectively, of the loxneo allele is also indicated. The probe used to
identify the diagnostic KpnI (K) and NheI (N) DNA fragments is indicated
by a hatched box. Other diagnostic restriction sites, including EcoRI (E)
and XbaI (X), are also indicated.
B: PCR strategy for routine genotyping. Forward (FT31, FT9) and reverse
(FT32) primers are indicated by open triangles. The sizes of the expected
diagnostic DNA fragments are also indicated.
C: Representative PCR analysis of tail DNA isolated from mice carrying the
indicated alleles.determined by Southern blot (data not shown) and PCR analy-
sis (Figures 1B and 1C). Crosses between FT+/− mice failed to
yield FT−/− animals. Crosses between FT+/lox mice resulted in
the generation of FT lox/lox animals with the expected Mendelian
ratio. These mice lived for over 2 years without obvious ana-
tomical or behavioral abnormalities.CANCER CELL : APRIL 2005
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Matings between FT+/− mice did not yield homozygous em-
bryos at embryonic stage 11.5 (E11.5) or older. Histological ex-
amination of decidual swellings at E7.5 revealed a significant
percentage of highly disorganized embryos with gross mor-
phological alterations, including loss of the embryonic layers
derived from the epiblast (Figure 2A). Only structures related to
the ectoplacental cone and trophoblast giant cells could be
morphologically identified. Loss of the epiblast in defective em-
bryos appeared to be a consequence of decreased cell prolif-
eration, as determined by a marked reduction of Ki67 immuno-Figure 2. FTase is required for early embryonic
development
A: H&E staining, Ki67 labeling, and TUNEL stain-
ing of representative sections from normal (top)
and abnormal (bottom) E7.5 embryos derived
from crosses between FT+/− mice. Abnormal em-
bryos lacking detectable embryonic layers are
likely to correspond to nonviable FT−/− embryos.
The percentage of abnormal embryos coin-
cided with the expected Mendelian ratio (25%)
for FT−/− embryos. Normal embryos display high
levels of Ki67-positive cells and no detectable
apoptotic cells. In contrast, abnormal embryos
have few Ki67-positive cells and multiple apo-
ptotic cells.
B: Proliferative properties of FT+/+ and FT−/− blas-
tocysts in culture. Blastocysts (E3.5) derived from
FT+/− crosses were placed on gelatin-coated
plates and cultured for 2 (E5.5), 4 (E7.5), and 6
(E9.5) days. Cells were then used for genotype
analysis. The inner cell mass (ICM) and tropho-
blast giant cells (T) are indicated.
C: Proliferative activity of FT+/+ and FT−/− cul-
tured blastocysts corresponding to E9.5 em-
bryos as determined by BrdU incorporation.
Phase contrast photographs (left) and DAPI
staining (right) are also included. Scale bars, 100
m in A and 4 m in B–C.CANCER CELL : APRIL 2005staining and increased apoptosis as revealed by high levels of
TUNEL staining (Figure 2A).
To determine whether loss of FTase also had an effect on
preimplantation embryos, we isolated E3.5 blastocysts from
crosses between FT+/− mice. After 48–72 hr in culture, all blas-
tocysts behave equally well in culture regardless of their geno-
type. They hatched and formed a multicomponent structure in
which the inner cell mass (ICM) grew as a mound on top of the
extraembryonic trophoblast cells (Figure 2B). However, after 4
days in culture, a stage equivalent to E7.5 embryos, the ICM
of FTase null embryos showed a dramatic decrease in cell pro-315
A R T I C L Eliferation (Figure 2B). These observations became even more
evident 2 days later, when few FT−/− ICM cells persisted in the
cultures and there was no detectable incorporation of bromo-
deoxyuridine (BrdU) (Figure 2C). In contrast, FT−/− trophoblasts
remained attached to the culture dish and continued to grow
in size at a rate similar to that of their wild-type counterparts,
indicating that FTase may not be required for survival of endo-
replicating cells (Figures 2B and 2C). These observations sug-
gest that the defects observed in FT−/− embryos are an intrinsic
property of the mutant embryonic cells.
Growth properties of FTase-deficient mouse
embryonic fibroblasts
Due to the early lethality of FT−/− embryos, we used conditional
FTase mutant mice to generate primary cultures of mouse em-
bryonic fibroblasts (MEFs). First, we crossed FT lox/lox animals
with RERTert/ert mice, a strain that carries an IRES-CreERT2
cassette (Brocard et al., 1997) inserted by homologous recom-
bination at the 3# end of the locus encoding the large subunit
of RNA polymerase II, between the terminator codon and the
polyadenylation signal (ert allele). This strategy allows bicis-
tronic expression of the inducible CreERT2 recombinase from
the same mRNA as the large subunit of RNA polymerase II
thanks to the knocked-in IRES sequences (our unpublished
data).
Six independent cultures of FT lox/lox;RERTert/ert MEFs de-
rived from three different embryos were cultivated in the pres-
ence of 4-hydroxy-tamoxifen (4OHT), a synthetic steroid
needed to activate CreERT2. Fully immortalized cultures were
submitted to Southern blot analysis to determine whether the
conditional lox allele had been completely excised. As il-
lustrated in Figure 3A, all cultures contained varying amounts
of null and lox alleles. To obtain a pure population of FT null
MEFs, we isolated single-cell clones and submitted them to
PCR analysis (Figure 3B). All 15 clones depicting an unambigu-
ous FT−/−;RERTert/ert genotype had a distinctly flat and polyhe-
dric shape (Figure 3C). These FTase-deficient MEFs did not
grow at high density and maintained a discernable intercellular
space, a phenotype likely to result from cytoskeletal alter-
ations. Indeed, the number of FT−/−;RERTert/ert cells in satu-
rated cultures was 1.48 ± 0.79 × 106 per 10 cm dish (n = 3),
whereas FT lox/lox;RERTert/ert MEFs reached saturation levels
that were three times higher (4.50 ± 0.12 × 106 per 10 cm dish;
n = 3). These FTase-deficient MEFs also displayed reduced
motility in an in vitro wound closure assay (Figure 3D).
FTase-deficient MEFs also proliferated less efficiently than
control MEFs (Figure 3E) and had reduced plating efficiency.
Whereas plating 5000 FT−/−;RERTert/ert cells derived from three
independent clones in a petri dish yielded 103 ± 7 colonies,
the same amount of control FT lox/lox;RERTert/ert MEFs led to
162 ± 3 colonies. Finally, quiescent FT−/−;RERTert/ert MEFs re-
entered the cell cycle with normal kinetics upon serum stimula-
tion (Figure 3F). However, the percentage of cells that entered
S phase was reduced by about 60% when compared with that
observed with FT lox/lox;RERTert/ert MEFs (Figure 3F).
Absence of FTase activity in FT−/− MEFs
To date, the locus encoding the catalytic subunit of FTase ap-
pears to be unique within the human and mouse genomes. Yet,
this fact does not preclude the existence of unrelated proteins
with putative FTase activity. Thus, we examined whether316Figure 3. Growth properties of FT−/− MEFs
A: Southern blot analysis of individual cultures of passage 14 FT lox/lox;
RERTert/ert MEFs exposed to 4OHT.
B: PCR analysis of single-cell clones isolated from 4OHT-treated FT lox/lox;
RERTert/ert MEF cultures. Migration of the lox and null alleles is indicated
by arrowheads.
C: Phase contrast photographs depicting the morphological appearance
of MEFs expressing (FT lox/lox;RERTert/ert MEFs) or lacking (FT−/−;RERTert/ert MEFs)
FTase. Scale bar, 8 m.
D: Growth repopulation after mechanical injury in representative cultures
of FT lox/lox;RERTert/ert MEFs (filled bars) and FT−/−;RERTert/ert MEFs (open bars).
Results are represented as percentage of area filled at the indicated times.
E: Proliferation of immortal FT lox/lox;RERTert/ert (filled circles) and FT−/−;
RERTert/ert (open circles) MEFs. Each time point was done in triplicate with
three different cell lines of each genotype, and the average value is repre-
sented. At least three independent experiments were performed with all
cell lines.
F: Kinetics of reentry in S phase upon serum stimulation of quiescent
FT lox/lox;RERTert/ert (filled circles) and FT−/−;RERTert/ert (open circles) MEFs. In
the description of the MEFs, the presence of the ert allele has been elimi-
nated for clarity.FT−/−;RERTert/ert MEFs had detectable levels of FTase activity.
Extracts derived from these cells failed to incorporate signifi-
cant levels of 3H-labeled farnesylpyrophosphate ([3H]-FPP) into
a biotin-labeled synthetic peptide substrate (biotin-YRASNRS-
CAIM-COOH) derived from the carboxy-terminal sequences of
human lamin B (Figure 4A). We also assayed FTase activity inCANCER CELL : APRIL 2005
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A: Extracts derived from FT lox/lox;RERTert/ert MEFs either before (filled circles)
or after (filled triangles) heat inactivation and from FT−/−;RERTert/ert MEFs
(open circles) were incubated with biotin-labeled lamin B peptide in the
presence of [3H]-FPP as described in the Experimental Procedures. The
means ± SD for three different protein preparations are shown.
B: Electrophoretic analysis of MDJ2 in FT lox/lox;RERTert/ert and FT−/−;RERTert/ert
MEFs. Migration of the MDJ2 protein isoforms is indicated.
C: (Top) Incorporation of [3H]-FPP into H-Ras in extracts derived from
FT lox/lox;RERTert/ert and FT−/−;RERTert/ert MEFs; (bottom) Western blot analysis
of H-Ras immunoprecipitated from the same extracts.
D: Isoprenylation of recombinant H-Ras protein in vitro. Recombinant H-Ras
protein was incubated with the indicated amount of cellular extract de-
rived from FT lox/lox;RERTert/ert or FT−/−;RERTert/ert MEFs in the presence of [3H]-
FPP or [3H]-GGPP. FTase (FTI) or GGTase (GGTI) inhibitors were added to
the reactions as indicated. Migration of the H-Ras protein in SDS-PAGE gels
is indicated by an arrowhead. All MEFs are homozygous for the ert allele.intact cells by determining the electrophoretic mobility of the
endogenous MDJ2, a chaperone protein known to be a FTase
substrate (Davis et al., 1998). As illustrated in Figure 4B, about
60% of MDJ2 expressed in FT−/−;RERTert/ert cells displayed
slower electrophoretic mobility likely to correspond to the non-
farnesylated isoform. Whether the fast migrating MDJ2 present
in FTase null cells is isoprenylated by GGTase I remains to be
determined.
Next, we determined the ability of these FTase-deficient cells
to farnesylate H-Ras. Total protein extracts from FT lox/lox;
RERTert/ert and FT−/−;RERTert/ert cells were incubated with [3H]-
FPP followed by immunoprecipitation with anti-H-Ras antibod-
ies. As illustrated in Figure 4C, only extracts from FT lox/lox;
RERTert/ert MEFs catalyzed the incorporation of [3H]-farnesyl
residues into H-Ras in spite of the presence of equal levels ofCANCER CELL : APRIL 2005H-Ras protein in both cell extracts. Finally, we performed a
similar, albeit more sensitive assay using recombinant H-Ras
protein. As depicted in Figure 4D, extracts from FT−/−;
RERTert/ert MEFs did not incorporate detectable [3H]-FPP into
recombinant H-Ras protein even under forced conditions (30
g of protein) in which control extracts could even misincorpo-
rate 3H-labeled geranylgeranylpyrophosphate ([3H]-GGPP), as
determined by using specific inhibitors (Figure 4C). Ablation of
FTase activity has no effect on GGTase, since FT−/−;RERTert/ert
cells had normal levels of GGTase I activity (7.9 pmol/mg pro-
tein/hr). These results indicate that FT−/−;RERTert/ert MEFs lack
FTase activity.
Ablation of FTase in postnatal mouse tissues
Next, we examined the consequences of eliminating FTase
during postnatal development. Ten-day-old (P10) FT lox/lox;
RERTert/ert or FTlox/−;RERTert/ert mice were exposed to 4OHT
for 8 weeks. At the end of treatment, FT lox alleles had been
efficiently excised in all tissues except muscle (Figure 5A), a
tissue in which the CreERT2 enzyme is not active in the RERT
strain (V.C., unpublished data). Extracts derived from liver and
lung tissues of 4OHT-treated animals had no significant levels
of FTase activity (Figure 5B). These 4OHT-treated mice will be
designated as FT;RERTert/ert regardless of whether they wereFigure 5. Lack of FTase in FT;RERTert/ert mice
A: Ablation of the gene encoding the catalytic β subunit of FTase in adult
tissues. Southern blot (top) and PCR (bottom) analysis of DNA isolated from
tissues of 2- and 4-month-old FT;RERTert/ert mice, respectively, generated
by continuous treatment of P10 FT lox/lox;RERTert/ert animals with 4OHT. The
migration of the DNA fragments diagnostic of the lox and null alleles is
indicated by arrowheads. Tissues included stomach (St), colon (C), kidney
(K), liver (Li), thymus (Th), spleen (Sp), muscle (M), lung (Lu), pancreas (P),
and testis (Te).
B: FTase activity in extracts derived from liver and lung tissues of FT lox/lox;
RERTert/ert mice before (filled circles) or after (filled triangles) heat inactiva-
tion and from FT;RERTert/ert mice (open circles). The means ± SD for protein
preparations from three different animals are shown.317
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since we did not observe any differences between the two co-
horts.
FT;RERTert/ert mice did not display obvious anatomical,
pathological, or behavioral defects for up to 18 months of age.
Moreover, crosses between FT;RERTert/ert males and wild-
type females led to progenies in which more than 80% of the
mice were FT+/−;RERT+/ert, demonstrating that FTase null male
germ cells are functional. The fertility of FT;RERTert/ert females
could not be assessed, since 4OHT treatment limits fertility
even in wild-type females. Histological analysis of a variety of
tissues of 2- to 3-month-old FT;RERTert/ert mice, including
bone marrow, colon, heart, kidney, liver, lung, lymph nodes,
mammary glands, pancreas, pituitary gland, salivary glands,
skin, spleen, stomach, testis, and thymus, did not reveal obvi-
ous histopathological alterations.
Stress responses in young mice lacking FTase
To test whether FTase was required during stress conditions,
10-week-old FTD;RERTert/ert mice were submitted to partial hep-
atectomy, wound healing, and erythropoietic regeneration after
severe bleeding. Livers (about 70% of total tissue) were surgically
removed from FT lox/lox;RERTert/ert and FTD;RERTert/ert mice (n =
6). Nine days later, mice were sacrificed, and their livers were
weighed. All animals displayed fully regenerated livers with no
obvious morphological or anatomical differences between the
untreated and the 4OHT-treated cohorts. Whereas FT lox/lox;
RERTert/ert livers weighed 2.15 ± 0.35 g, FTD;RERTert/ert livers
had a weight of 2.40 ± 0.60 g. Genotype analysis of the regen-
erated liver tissue exclusively revealed the presence of the FT
null allele (data not shown). FTD;RERTert/ert mice also reco-
vered normally from skin wounds in the mid-dorsal region and
from severe bleeding (data not shown).
Delayed wound healing in adult FTase-deficient mice
Six-month-old FTD;RERTert/ert mice were submitted to the
same stress conditions except for partial hepatectomy, since
at this age even wild-type mice have drastically reduced ca-
pacity to regenerate liver tissue. In the wound healing para-
digm, we did not observe significant differences in the gross
appearance of the wounds of FT lox/lox;RERTert/ert and FTD;
RERTert/ert mice (n = 12) 3 days after the incision. By day 5, all
wounds were covered with a dry scab. All wounds were healed
by day 9 in control mice. At this time, however, only 70% of the
wounds in FTD;RERTert/ert mice had healed. Complete wound
healing in these FTase-defective mice could not be observed
until 12 days after incision. These observations indicate that
FTD;RERTert/ert mice retain their full capacity to heal skin
wounds. However, the regeneration process in these FTase-
deficient animals is delayed by about 30%.
Maturation defects in erythroid cells
of adult FTase-deficient mice
Morphologic examination of 6-month-old FTD;RERTert/ert mice
revealed a minor but consistent decrease (about 20%) in the
size of their spleens. Moreover, FTase-defective spleens had a
significantly larger pool of proliferating Ter119+ erythroid cells
(7.7% ± 1.7% of total spleen cells versus 1.8% ± 0.5% in con-318Figure 6. Erythroid defects in adult FTase mutant mice
A and B: Levels of splenic Ter119+ erythroid (A) and GR1+ and CD11b+ (B)
myeloid cells of 4OHT-treated FT+/+;RERTert/ert and FT;RERTert/ert 6-month-
old mice before (−) and 48 hr after (+) removal of 0.8 ml of blood. The means
± SD for three different animals from each genotype are shown.
C: H&E-stained sections of the spleens depicted in A and B (original magni-
fication 100×).trol mice) (Figure 6A). FTD;RERTert/ert spleens also had in-
creased pools of myeloid cells compared to those of 4OHT-
treated FT+/+;RERTert/ert mice, including GR1+ (22.77% ±
5.93% versus 10.45% ± 2.56% of Ter119− cells) and CD11b+
(26.81% ± 1.5% versus 13.87% ± 0.45% of Ter119− cells) cells
(Figure 6B). Whether the observed increase in myeloid cells is
a direct consequence of FTase loss or an indirect effect caused
by compromised erythroid maturation remains to be deter-
mined.
Removal of 0.8 ml of blood from 6-month-old 4OHT-treated
FT+/+;RERTert/ert and FTD;RERTert/ert animals (n = 6) resulted in
a significant increase in the size of their spleens after 48 hr.
This increase was more pronounced in wild-type mice (from
142 ± 7 to 245 ± 2 mg, 72% increase) than in those mice lack-CANCER CELL : APRIL 2005
A R T I C L Eing FTase (from 113 ± 4 to 175 ± 26 mg, 54% increase). Histo-
logical examination of these spleens revealed a significant de-
pletion of reactive splenic erythropoietic centers in FTD;
RERTert/ert but not in FT+/+;RERTert/ert mice (Figure 6C). No dif-
ferences were observed in the white pulp. Flow cytometry
analysis indicated that, upon bleeding, the splenic erythroid
compartment (Ter119+ cells) of 4OHT-treated FT+/+;RERTert/ert
mice increased by as much as 15-fold, whereas that of
FTD;RERTert/ert animals only increased by 2.8-fold (Figure 6A).
We also observed different responses in myeloid cells.
Whereas the number of GR1+ and CD11b+ cells increased by
2.5- to 3-fold in the spleens of 4OHT-treated FT+/+;RERTert/ert
mice, no such increase could be observed in FTase-defective
animals (Figure 6B). No differences were observed in Ter119+,
GR1+, and CD11b+ cells in bone marrow and peripheral blood
before or after bleeding.
Ablation of FTase in tumors harboring K-ras oncogenes
To assess whether loss of FTase activity had an effect on tumor
development, we ablated FTase in mice carrying lung adeno-
carcinomas induced by an endogenous K-ras oncogene
(Guerra et al., 2003). To this end, we crossed FT lox/lox;RERTert/ert
animals with K-ras+/V12 mice, a strain that carries a conditional
K-ras allele activated by a G12V mutation (Guerra et al., 2003).
P10 FT lox/lox;K-ras+/V12;RERTert/ert and FT+/+;K-ras+/V12;
RERTert/ert mice (n = 18) were treated with 4OHT for 24 weeks.
Both cohorts developed multiple lung adenomas and adeno-
carcinomas at about 7 months of age (Guerra et al., 2003). As
illustrated in Figure 7A, the number and size of adenomas pre-
sent in both groups of mice were similar. Moreover, the percen-
tage of adenomas that had progressed to adenocarcinomas at
the time of death was also similar in both cohorts (22% in con-
trol mice versus 20% in FTase-deficient animals).
Other pathologies observed in 4OHT-treated FT+/+;K-ras+/V12;
RERTert/ert mice, including occasional facial and anal papillo-
mas as well as hyperplasia in the Harderian glands, were also
observed in FTD;K-ras+/V12;RERTert/ert animals with similar inci-
dence (Figure 7B). Complete loss of FTase sequences in tu-
mors isolated from FTD;K-ras+/V12;RERTert/ert mice was verified
by PCR analysis (data not shown). These results indicate that
K-ras oncogenes induce neoplastic lesions regardless of the
presence or absence of FTase.
Loss of FTase does not prevent activation of H-ras
oncogenes in carcinogen-induced tumors
Previous observations indicate that K-Ras oncoproteins can be
crossprenylated by GGTase I in cells treated with FTIs (Lerner
et al., 1997; Rowell et al., 1997; Whyte et al., 1997). Whether
crossprenylation is responsible for the lack of effect of eliminat-
ing FTase in K-ras-induced tumors remains to be determined.
In contrast, H-Ras cannot be isoprenylated by GGTase I
(James et al., 1995) (Figure 4D). Therefore, we examined the
requirement of FTase for H-ras-induced oncogenesis in vivo.
To this end, we submitted FTase-defective mice to the classical
7,12 dimethyl-benzanthracene (DMBA) plus 12-o-tetradeca-
noylphorbol-13-acetate (TPA) skin carcinogenesis protocol in
which H-ras oncogenes are frequently activated (Balmain and
Pragnell, 1983).
We first examined whether ablation of FTase before exposure
to DMBA had a benefit in tumor prevention. FT lox/lox;RERTert/ert
mice (n = 20) were split into two cohorts and either left un-CANCER CELL : APRIL 2005Figure 7. Effect of FTase ablation on tumor development
A: Number of adenomas and adenocarcinomas of the indicated sizes in
lungs of 4OHT-treated FT+/+;K-ras+/V12;RERTert/ert (filled columns) (n = 9) and
FT;K-ras+/V12;RERTert/ert (open columns) (n = 9) mice.
B: Percentage of mice described in A with papillomas and hyperplastic
Harderian glands.
C: Number of papillomas in 2-month-old FT lox/lox;RERTert/ert (n = 10) and
FT;RERTert/ert (n = 10) mice treated with a single dose of DMBA followed
by treatment with TPA for 12 additional weeks. The average number of
papillomas per mouse of less (open columns) or more (gray columns) than
4 mm of diameter is indicated.
D: Number of papillomas in FT lox/lox;RERTert/ert (n = 18) mice treated at P10
with a single dose of DMBA followed by treatment with TPA for 12 addi-
tional weeks. FT;RERTert/ert (n = 18) mice were generated by treatment of
FT lox/lox;RERTert/ert animals with 4OHT 2 weeks after exposure to DMBA for
the duration of the experiment (32 weeks). The average number of papillo-
mas per mouse of less than 4 mm of diameter (open columns), between 4
and 8 mm of diameter (gray columns), and more than 8 mm of diameter
(dark columns) is indicated.treated or treated with 4OHT for 20 weeks to remove the FT
lox allele. When these mice became 2 months old, both co-
horts were exposed to a single dose of DMBA (25 g/mouse)
followed by repeated exposure to TPA for 12 additional weeks.
As illustrated in Figure 7C, both cohorts of mice developed
skin papillomas with similar incidence and kinetics regardless
of the presence or absence of FTase. Genetic analysis of indivi-
dual papillomas (n = 9) isolated from FTD;RERTert/ert mice re-
vealed that the FT lox alleles had been completely excised in
these tumors (data not shown). To our surprise, H-ras onco-
genes were present in both FT lox/lox;RERTert/ert and FTD;319
A R T I C L ERERTert/ert mice with equal incidence (5 out of 9 and 6 out of
11 papillomas, respectively). All H-ras oncogenes were acti-
vated by the same CAA/CTA transversion in codon 61 (see
the Supplemental Data available with this article online). We
did not observe any significant differences in the size or patho-
logical appearances between those tumors harboring H-ras
oncogenes and those negative for this oncogene. These obser-
vations indicate that loss of the β subunit of FTase does not
protect mice from skin tumor development, regardless of
whether such tumors contain H-ras oncogenes or are induced
by different mechanisms.
FTase ablation during tumor development
We also examined whether loss of FTase activity after tumor
initiation had therapeutic benefit. Mice (n = 36) were either
treated or not treated with 4OHT 2 weeks after the carcino-
genic insult, a time when papillomas were still undetectable. At
15 weeks, both groups of mice had developed a similar num-
ber of papillomas (Figure 7D). However, at 20 to 25 weeks,
FTD;RERTert/ert mice displayed a significant reduction in the
average number of papillomas per mouse (1.3 versus 4.7) and
in tumor size (2.1 versus 4.7 mm of diameter) (Figure 7D). All
papillomas (n = 10) examined from FTD;RERTert/ert mice had
lost their FT lox alleles and carried H-ras oncogenes activated
by the same CAA/CTA transversion in codon 61 (see the
Supplemental Data). As illustrated in Figure 8A, the levels of
expression of H-Ras protein in these papillomas were in-
creased by about 5- to 8-fold as compared with those present
in normal skin. A similar increase in H-Ras expression was ob-
served in papillomas derived from FTD;RERTert/ert mice (Fig-
ure 8A).
Previous studies have indicated that the transforming activity
of H-Ras oncoproteins requires their association with the
plasma membrane, a process initiated by farnesylation of its
carboxy-terminal CaaX motif (Downward, 2003; Sebti and Der,
2003). To examine whether H-Ras proteins were associated
with membranous structures in tumors devoid of FTase, we
fractionated cell extracts derived from FT lox/lox;RERTert/ert and
FTD;RERTert/ert papillomas. As depicted in Figure 8B, Western
blot analysis revealed that at least half of the H-Ras protein
expressed in papillomas lacking FTase was associated with the
membranous P100 fraction (Figure 8B). As expected, the per-
centage of H-Ras protein present in the membrane fraction of
control papillomas was close to 90% (Figure 8B). To determine
whether the membrane localization of H-Ras in the absence of
FTase is a unique property of papillomas or even a conse-
quence of its oncogenic activation, we determined the subcel-
lular localization of H-Ras in MEFs lacking FTase, a cell type in
which H-Ras does not incorporate farnesyl residues (see Fig-
ures 4C and 4D). As shown in Figure 8C, the endogenous
H-Ras protein expressed in FT−/−;RERTert/ert MEFs is also as-
sociated with membranous structures. Ectopic overexpression
of H-Ras in these cells results in the presence of a limited per-
centage of the total H-Ras protein in the soluble fraction, a
property also observed in control FT lox/lox;RERTert/ert MEFs
(Figure 8C). These observations challenge the widely held con-
cept that farnesylation is required for the association of H-Ras
with membranes and for malignant transformation, at least in
skin tumors.320Figure 8. Expression levels and subcellular localization of H-Ras in tumor and
normal cells lacking FTase
A: Western blot analysis of H-Ras in papillomas derived from FT lox/lox;RERTert/ert
and FT;RERTert/ert mice. Skin tissue obtained from FT+/+;RERTert/ert mice
treated with 4OHT and FT+/+;RERTert/ert MEFs were used as a reference. β
actin was used as loading control.
B: Subcellular localization of H-Ras in papillomas. Total protein extracts from
FT lox/lox;RERTert/ert and FT;RERTert/ert papillomas were fractionated into
membranous (P100) and cytosolic (S100) fractions. H-Ras immunoprecipi-
tates were fractionated in SDS gels and identified by Western blot analysis
with antibodies specific for H-Ras.
C: Subcellular localization of H-Ras in fibroblasts null for FTase. Lysates from
untransfected FT lox/lox;RERTert/ert and FT−/−;RERTert/ert MEFs (left) and from the
same MEFs transfected with a plasmid containing the H-ras gene (right)
were fractionated into membranous (P100) and cytosolic (S100) fractions
and analyzed as described above. H-Ras FT lox/lox;RERTert/ert and H-Ras
FT−/−;RERTert/ert cells express high levels of H-Ras (5- to 10-fold higher than
untransfected MEFs). Migration of H-Ras is indicated by arrowheads. All
MEFs are homozygous for the ert allele.Discussion
Available evidence indicates that eukaryotic genomes, from
yeast to humans, encode a single FTase made up of a specific
catalytic subunit (β subunit) and a regulatory subunit (α sub-
unit) shared with GGTase I. In agreement with these observa-
tions, ablation of the third exon of the gene encoding its β sub-
unit results in complete loss of FTase activity, as determined
by using three different substrates including H-Ras. In yeast,
FTase-deficient cells are viable but display significant growth
defects (Powers et al., 1986). The viability of these cells has
been attributed to compensatory mechanisms involving cross-
prenylation by GGTase I (Trueblood et al., 1993). FTase-defi-
cient MEFs proliferate well, but their growth rate is significantly
slower than that of wild-type cells. Moreover, quiescent FTase
null MEFs do not reenter the cell cycle upon mitogenic stimuli
as efficiently as their normal counterparts, suggesting a signal-CANCER CELL : APRIL 2005
A R T I C L Eing defect possibly involving inefficient activation of Ras pro-
teins. However, it is also possible that lack of farnesylation of
certain cell cycle proteins, such as the CENP kinetochore pro-
teins, may contribute to this phenotype. FTase-deficient MEFs
have a flat polygonal appearance and fail to grow as dense
cultures. Moreover, their motility in standard in vitro wound as-
says is compromised, suggesting cytoskeletal defects (Zhang
and Casey, 1996; Prendergast, 2001).
In vivo, FTase null embryos proliferate well and are able to
implant in the maternal uterus. However, they undergo massive
apoptosis a few hours after implantation. In vitro, FTase-defi-
cient blastocysts (E3.5) appear normal and proliferate well up
to 5–6 days after fertilization. However, they cease proliferation
thereafter, indicating that the strict requirement for FTase is a
cell autologous property. These observations could be ex-
plained by the absolute requirement of yet unidentified sub-
strate(s) to undergo farnesylation during or immediately after
implantation. However, it is also possible that farnesylation
may be essential for even earlier stages of embryonic cell pro-
liferation, but such requirement is provided by the maternal en-
zyme. In either case, our results establish that FTase activity is
essential for cell proliferation during early embryogenesis (at
least after E5.5) and that such requirement cannot be compen-
sated by crossprenylation by either GGTase I or other protein
isoprenyltransferases.
Protein farnesylation, however, is not essential for postnatal
development. Young animals lacking FTase in most of their
tissues develop normally to adulthood. Remarkably, FTD;
RERTert/ert male mice efficiently transmit their FT null allele to
their offspring, demonstrating that FTase activity is not essen-
tial for meiotic cell division, at least in males. Likewise, liver
tissue regenerates in the absence of protein farnesylation after
severe (70%) hepatectomy, regardless of the presence or ab-
sence of FTase activity. Young FTase-defective mice also reco-
vered normally from other stress conditions, such as skin
wounds and severe bleeding. Thus, unlike MEFs, postnatal fi-
broblasts respond normally to mitogenic stimuli. Likewise, he-
matopoiesis does not appear to be affected by lack of protein
farnesylation in these young mice. These results suggest that
protein farnesylation may not be required after birth. Alterna-
tively, farnesylated proteins may undergo crossprenylation in
postnatal tissues more efficiently than in embryonic cells.
FTase is required for proper responses to stress conditions in
adult mice. Six-month-old FTase-deficient mice have delayed
wound healing response (30% longer than wild-type animals).
These mutant mice also display delayed maturation of ery-
throid precursor cells, as determined by a significant increase
of proliferating progenitors in their spleens. This defect became
more pronounced during response to severe bleeding. How-
ever, we did not observe significant defects in their bone mar-
row, suggesting that lack of FTase affects proliferation of com-
mitted erythroid precursors but not of pluripotent stem cells.
Protein farnesylation is the first step of a complex post-
translational process required for proper biological activity of
CaaX-containing proteins (Zhang and Casey, 1996). Farnesy-
lated proteins are recognized by specific endopeptidases that
remove the carboxy-terminal aaX tripeptide (Boyartchuk et al.,
1997). In S. cerevisiae, this process is carried out by two inde-
pendent zinc endopeptidases, Rce1 and Afc1 (Boyartchuk et
al., 1997). The mammalian homolog of the yeast RCE1 gene
has been recently isolated (Otto et al., 1999). Ablation of rce1CANCER CELL : APRIL 2005in mice results in either late embryonic or early postnatal lethal-
ity (Kim et al., 1999). The longer survival of rce1 null embryos
compared to those lacking FTase is likely to be due to sub-
strate proteins retaining partial function, since they can be iso-
prenylated even though postprenylation processing is abol-
ished. rce1 null MEFs also displayed retarded growth, at least
partially due to the compromised association of Ras proteins
with cellular membranes (Bergo et al., 2002).
Removal of the aaX sequence exposes the α-carboxyl group
of the farnesylcysteine residue to a specific isoprenylcysteine
methyltransferase (ICMT). ICMT was first identified in S. cere-
visiae as the product of STE14, a gene necessary for the prod-
uction of the a mating factor, but not for cell survival (Hrycyna
et al., 1991). A related gene, ICMT, has been recently identified
in human cells and shown to be functionally equivalent (Dai et
al., 1998). Mice lacking Icmt die at about E10.5 (Bergo et al.,
2001), a stage considerable later than that at which mice lack-
ing FTase die. Icmt-defective fibroblasts grow more slowly than
wild-type cells and are significantly resistant to transformation
by K-ras oncogenes (Bergo et al., 2004). Interestingly, this
property may not be a direct consequence of loss of activity of
K-Ras but rather due to increased expression of the cell cycle
inhibitor p21Cip1, since K-ras oncogenes can efficiently trans-
form Icmt-defective MEFs lacking p21Cip1 (Bergo et al., 2004).
Moreover, Icmt null MEFs are also resistant to an oncogenic
version of B-Raf, a nonprenylated protein that acts down-
stream of K-Ras (Bergo et al., 2004).
Much of the interest in protein farnesylation stemmed from
the hypothesis that this posttranslational modification may be
essential for the transforming activity of Ras oncoproteins
(Zhang and Casey, 1996). The limited success of FTIs in early
clinical trials has dampened some of this enthusiasm (Down-
ward, 2003; Sebti and Der, 2003). These observations might be
due, at least in part, to the fact that K-Ras4B, the Ras isoform
most frequently mutated in human cancer, can undergo cross-
prenylation by GGTase I and thus could be insensitive to FTase
inhibition (Lerner et al., 1997; Rowell et al., 1997; Whyte et al.,
1997). Loss of FTase activity in lung adenomas induced by ac-
tivation of an endogenous K-ras oncogene (Guerra et al., 2003)
had no effect on either tumor incidence or tumor development.
Whether these observations are due to alternative geranylgera-
nylation as suggested by the in vitro studies or to a different
mechanism remains to be elucidated.
Unlike K-Ras, H-Ras proteins can only be isoprenylated by
FTase. Loss of FTase activity by postnatal ablation of the gene
encoding the catalytic β subunit had no significant effect on
skin tumor formation (papillomas) in the DMBA + TPA protocol,
a tumor model known to involve the reproducible activation
of H-ras oncogenes (Balmain and Pragnell, 1983). Surprisingly,
about two-thirds of these FTase-negative papillomas harbored
H-ras oncogenes, the same percentage observed in FT lox/lox;
RERTert/ert control mice. These observations indicate that, in a
physiological environment, H-ras oncogenes contribute to tu-
mor development in the absence of FTase activity.
Removal of FTase after initiation of tumorigenesis had a sig-
nificant effect on tumor progression as both the number of
papillomas per animal and their average size were significantly
reduced. Interestingly, those papillomas resistant to FTase ab-
lation still carried H-ras oncogenes and retained the same
levels of H-Ras expression as control tumors expressing the
enzyme. Most surprisingly, a significant fraction of the H-Ras321
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membranous structures. Previous studies had conclusively
demonstrated that replacement of the cysteine residue of the
CaaX motif by serine, a mutation that prevents farnesylation of
the H-Ras oncoprotein (Casey et al., 1989; Hancock et al.,
1989), abolished the transforming activity of retroviral v-H-ras
oncogenes in culture (Willumsen et al., 1984a; Willumsen et al.,
1984b). These and other related observations have led to the
widely held concept that nonfarnesylated H-Ras oncoproteins
had no transforming activity, since they could not be properly
localized in the plasma membrane. However, our results indi-
cate that H-Ras oncoproteins expressed in cells devoid of
FTase activity, and therefore presumed to be nonfarnesylated
(see Figure 4), can associate with membranous structures and
retain transforming activity, at least in DMBA-induced skin tu-
mors. These observations make it necessary to reexamine the
requirements for the association of H-Ras proteins with cellular
membranes. We hypothesize that nonfarnesylated H-Ras pro-
teins may interact with membranes in the absence of farnesyla-
tion through the palmitoyl residues attached to cysteines in po-
sitions 181 and 184. This posttranslational modification might
be compromised in mutant H-Ras proteins in which cysteine
186, the target for farnesylation, has been replaced by serine.
Elucidation of the posttranslational modifications of H-Ras pro-
teins in FTase-defective cells by direct chemical analysis
should help to establish the minimal requirements for their as-
sociation with membranous structures and for transforming ac-
tivity.
In summary, our observations illustrate that FTase is dispens-
able for tumor development induced by an endogenous K-ras
oncogene, the ras oncogene most frequently activated in can-
cer patients. FTase is also dispensable for initiation of benign
skin papillomas driven by H-ras oncogenes. However, removal
of FTase after tumor initiation provides limited therapeutic ben-
efit by decreasing the rate of tumor progression. Whether loss
of FTase has more pronounced activity in other experimental
tumor systems remains to be determined. Use of genetic ap-
proaches such as those described here should help to define
those targets essential for tumor development.
Experimental procedures
Gene targeting and genotyping strategies
We have targeted the catalytic β subunit of FTase in ES cells by a strategy
consisting in inserting three loxP sites flanking exon 3 and a PGK-neo cas-
sette (loxneo allele) (Figure 1A). Detailed information regarding the genera-
tion of the targeting vector as well as the PCR strategy to identify wild-type,
conditional (lox), and null (−) alleles can be found in the Supplemental Data.
Histology and cell culture assays
E7.5 deciduas or adult tissues were surgically removed, fixed in 10% buf-
fered formalin, and embedded in paraffin using standard procedures. Sec-
tions (6 m) were stained with hematoxylin and eosin (H&E). TUNEL assays
were performed using the in situ cell death detection kit (Roche). Cell prolif-
eration was determined by immunostaining with anti-Ki67 antibodies (Bio-
technologies). Blastocysts (E3.5) were collected by uterine flush with M2
medium (Sigma) and individually cultured on gelatin-coated 96-well plates.
For BrdU labeling, blastocysts were incubated for 2 hr with 10 M BrdU.
BrdU-positive cells were detected with BrdU detection kit I (Roche) accord-
ing to the manufacturer’s instructions. MEFs were isolated from FT lox/lox;
RERTert/ert E13.5 embryos and cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 2 mM glutamine, 1% penicillin/streptomy-
cin and 10% calf serum as described (Malumbres et al., 2004) in the ab-
sence or presence of 4OHT. Proliferation and S phase entry assays were322also carried out as previously described (Malumbres et al., 2004). For in
vitro motility assays, confluent monolayers were subjected to mechanical
injury with an adaptor scraper, and images were recorded every 10 min for
the required amount of time with a confocal microscope (Leica SP2).
Animal treatments
Mice were injected intraperitoneally three times a week with 0.5 mg of oil-
homogenized 4OHT (Sigma). Two-month-old mice were hepatectomized as
previously described (Higgins and Anderson, 1931). Two hours before sacri-
fice, mice were injected with 60 g of BrdU/g of body weight to analyze
cell proliferation. For wound healing experiments, mice (2 and 6 month old)
were anesthetized, their backs were shaved, and a circular full-thickness
wound (6 mm in diameter) was created by excision of the skin with curved
scissors. For bleeding experiments, 0.8 ml of blood was taken from the eye
of 2- and 6-month-old animals. Before bleeding, an analgesic was admin-
istrated. For carcinogenesis experiments, mice were treated with a single
dose of DMBA (Sigma) (25 g for 10-week-old mice and 0.5 mg for P10
mice) followed by exposure to TPA (Sigma) (12.5 g twice weekly) for a
total of 12 weeks.
Flow cytometry
Cells obtained from spleen and bone marrow were washed, resuspended
in PBS, and incubated with PharM Lyse (Pharmigen). Cell surface markers
used to identify hematopoietic cell populations included CD3, CD4, CD8,
CD11b, CD45, CD16/CD32, B220, GR1, IL-7aR, Pan-NK (DX-5), and Ter119
(Pharmigen). Cell populations were quantified using a BD Biosciences (FAC-
Scan). In each case, 20,000 events were collected.
Subcellular fractionation and Western blot analysis
Membrane (P100) and cytosolic (S100) fractions were isolated according to
established protocols (Bergo et al., 2002). H-Ras was immunoprecipitated
from 1 mg of P100 and S100 fractions with specific antibodies
(Ab-1; Oncogene Research Products). Western blots were performed using
different H-Ras-specific antibodies (C20; Santa Cruz Biotechnology), or an-
tibodies against HDJ2 (MDJ2-human homolog, KA2A5.6; NeoMarkers) and
β-actin (AC-15; Sigma). Antibodies were detected with the appropriate
horseradish peroxidase-linked secondary antibody and visualized with an
enhanced chemiluminescent (ECL) system (Amersham).
FTase activity assays
FTase and/or GGTase I activities were measured either using the [3H] SPA
enzyme assay kit (Amersham) or by measuring incorporation of [3H]-FPP or
[3H]-GGPP into a recombinant H-Ras protein by cytosolic fractions pre-
pared from MEFs as previously described (Fiordalisi et al., 2003). For the
incorporation of [3H]-FPP on the endogenous H-Ras protein, we incubated
1 mg of total protein extract in 1 ml of assay buffer ([3H] SPA enzyme assay
kit; Amersham) containing 12 M [3H]-FPP (12 Ci/mmol; Amersham). H-Ras
was immunoprecipitated as described above, resolved on 12% SDS-PAGE
gels, and exposed to film.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures
and one supplemental figure and can be found with this article online at
http://www.cancercell.org/cgi/content/full/7/4/313/DC1/.
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